X chromosome inactivation does not necessarily determine the severity of the phenotype in Rett syndrome patients

Abstract

Rett syndrome (RTT) is a severe neurological disorder usually caused by mutations in the MECP2 gene. Since the MECP2 gene is located on the X chromosome, X chromosome inactivation (XCI) could play a role in the wide range of phenotypic variation of RTT patients; however, classical methylation-based protocols to evaluate XCI could not determine whether the preferentially inactivated X chromosome carried the mutant or the wild-type allele. Therefore, we developed an allele-specifc methylation-based assay to evaluate methylation at the loci of several recurrent MECP2 mutations. We analyzed the XCI patterns in the blood of 174 RTT patients, but we did not fnd a clear correlation between XCI and the clinical presentation. We also compared XCI in blood and brain cortex samples of two patients and found diferences between XCI patterns in these tissues. However, RTT mainly being a neurological disease complicates the establishment of a correlation between the XCI in blood and the clinical presentation of the patients. Furthermore, we analyzed MECP2 transcript levels and found diferences from the expected levels according to XCI. Many factors other than XCI could afect the RTT phenotype, which in combination could infuence the clinical presentation of RTT patients to a greater extent than slight variations in the XCI pattern